Nasal Obstruction and Olfactory Losses

Sponsor
Ohio State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05920330
Collaborator
(none)
330
1
1
71.2
4.6

Study Details

Study Description

Brief Summary

About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.

Condition or Disease Intervention/Treatment Phase
  • Other: Nasal Plug
N/A

Detailed Description

Nasal sinus disease is one of the most common medical conditions in the US, affecting an estimated 13% of adults, or some 30 million people, and responsible for $5.8 billion in health care expenditures annually (National Health Interview Survey 2009, CDC). Nasal obstruction and smell loss are two of the major symptoms of the disease; however, the field currently lacks a clear, objective understanding of the mechanisms causing these symptoms, which thwarts effective treatment. For example, patients' complaints of nasal obstruction correlate poorly or inconsistently with objective measurements of actual physical obstruction. Without validated clinical tools, the current treatment of these symptoms relies primarily on the patient's subjective feedback and the doctor's personal training and experience, which can lead to inconsistent and unsatisfactory outcomes.

Through a series of preliminary studies, the investigators demonstrated that the symptom of nasal obstruction may be caused not by obstruction per se but by poor sensing of airflow during breathing or sensing may be worsened by impaired trigeminal function. However, which trigeminal sensory regions and what nasal airflow anomalies are most critical in disrupting the sensing of airflow are still unknown. In Aim 2, the investigators will investigate the efficacy of a novel patent-pending "nasal aid" to improve patients' symptoms by modulating nasal airflow and trigeminal sensory feedback and to improve future treatment outcomes based on what the investigators have learned and will continue to learn about the airflow trigeminal perception mechanisms.

The outcomes from this research may potentially validate several novel clinical tools to better identify factors that most affect patients' obstructive symptoms and to relieve symptoms by modulating nasal airflow patterns. The ultimate goal is to assist patients and clinicians in planning effective, well-informed, personalized treatment strategies, potentially saving millions of healthcare dollars annually while improving patient satisfaction.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
330 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Patients experiencing olfactory impairment and/or nasal obstruction, self-referred to participate in the research study.Patients experiencing olfactory impairment and/or nasal obstruction, self-referred to participate in the research study.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Novel Mechanisms and Therapeutic Approaches for Nasal Obstruction and Olfactory Losses
Actual Study Start Date :
Jan 25, 2023
Anticipated Primary Completion Date :
Jul 31, 2027
Anticipated Study Completion Date :
Dec 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Other: Single Arm

A device-nasal plug will be self-inserted into the nose with a diagonal channel embedded to redirect nasal airflow patterns to different nasal regions. A nose clip will be used to pinch the nose externally, similar to what synchronized swimmers use.

Other: Nasal Plug
Please see the arm description for details.
Other Names:
  • Swimmer's nose clip
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Nasal Obstruction Symptom Evaluation (NOSE) questionnaire [3 time points: 1-baseline, 2-after the applications of nasal aid (done on the first day of testing), and 3- 8 weeks after surgery.]

      A clinically validated 5 item questionnaire to document general nasal obstruction. symptoms severity.

    2. Change in Visual Analog Scale (VAS) of nasal obstruction [3 time points:1-baseline, 2-after the applications of nasal aid (done on the first day of testing) and 3-8 weeks after surgery.]

      A visual analog scale of nasal obstruction (VAS), with ratings from 0 to 10 (0 = completely clear; 10 = completely obstructed).

    3. Change in Empty Nose Syndrome 6-Item Questionnaire (ENS 6 Q) [3 time points:1-baseline, 2-after the applications of nasal aid (done on the first day of testing) and 3-8 weeks after surgery.]

      A validated ENS-specific symptom questionnaire.

    Secondary Outcome Measures

    1. Change in Sino-nasal Outcome Test (SNOT-22) [1-baseline (done on the first day of testing)and 2- 8 weeks after surgery]

      A validated questionnaire documenting general nasal sinus symptoms.

    2. Change in nasal resistance [1-baseline (done on the first day of testing) and 2- 8 weeks after surgery]

      Anterior rhinomanometry will be used to measure airflow and pressures during normal breathing.

    3. Change in rhinomanometry [1-Baseline (done on the first day of testing) and 2- 8 weeks post-surgery]

      The narrowest area of the nasal airway measured by an acoustic rhinometry.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Smell Loss complaints

    2. Nasal Obstruction

    Exclusion Criteria:
    1. Congenital olfactory losses

    2. Nasal polyps, blocking the olfactory cleft

    3. Significant atrophy

    4. Cystic fibrosis

    5. Wegeners or any other connective tissue disorder

    6. Head trauma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Eye and Ear Institute, 915 Olentangy River Road, ENT, Suite 4000 Columbus Ohio United States 43212

    Sponsors and Collaborators

    • Ohio State University

    Investigators

    • Principal Investigator: Kai Zhao, Ph.D, Associate Professor

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kai Zhao, Associate Professor, Ohio State University
    ClinicalTrials.gov Identifier:
    NCT05920330
    Other Study ID Numbers:
    • 2015H0262
    First Posted:
    Jun 27, 2023
    Last Update Posted:
    Jun 29, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 29, 2023